Clinical trials: Adnexal Tumor
Polycystic Ovary Syndrome, Familial Partial Lipodystrophy
Identification of Women With Severe Insulin Resistant Syndromes of Genetic Origin Among Patients With "Classic" Polycystic Ovary Syndrome (PCOS)
Diagnostic case-control study (1 case for 2 controls). Inclusion of patients with severe insulin resistance syndrome of genetic origin, then inclusion of controls: patients examined for PCOS in day hospital with matching age (+/…
- Conditions
- Polycystic Ovary Syndrome, Familial Partial Lipodystrophy, LMNA (LaMin Nuclear A) Related Disorders
- Trial name
- ANDROLIPO (NCT07412028)
- Testing
- Genetic analysis, Biological analysis, imaging test
- Where
- France
- Volunteers
- 81 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Polycystic Ovary Syndrome
SGLT2 Inhibitors in Patients With PCOS
Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with a prevalence of 5% to 15% in premenopausal women. Patients with PCOS presents as abnormal menstruation, ovulation disorders and/or hyperandrogenemia, and often…
- Trial name
- PCOS (NCT04700839)
- Testing
- SGLT2 inhibitors, Metformin
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Shanghai 10th People's Hospital
Ovarian Cancer
ICON8: Weekly Chemotherapy in Ovarian Cancer
The purpose of this study is to determine if weekly chemotherapy (i.e. giving paclitaxel or carboplatin at a lower dose every week) is more effective than standard chemotherapy (paclitaxel and carboplatin given once every three…
- Trial name
- ICON8 (NCT01654146)
- Testing
- Carboplatin, Paclitaxel
- Where
- United Kingdom
- Volunteers
- 1,485 people
- Sponsor
- Medical Research Council
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02001623
- Testing
- Tisotumab Vedotin (HuMax-TF-ADC)
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 195 people
- Sponsor
- Seagen Inc.
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This randomized phase III trial studies bevacizumab and intravenous (given into a vein) chemotherapy to see how well they work compared with bevacizumab and intraperitoneal (given into the abdominal cavity) chemotherapy in…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT00951496
- Testing
- Bevacizumab, Carboplatin, Cisplatin
- Where
- 503 sites in United States
- Volunteers
- 1,560 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Low Grade Serous Carcinoma
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
This is a phase II, single arm, multi-centre study to assess the efficacy of pembrolizumab in combination with platinum-based chemotherapy (investigator's choice: carboplatin + gemcitabine or carboplatin + pegylated liposomal…
- Conditions
- Ovarian Cancer, Low Grade Serous Carcinoma, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- PERCEPTION (NCT04575961)
- Testing
- Pembrolizumab
- Where
- 2 sites in Germany
- Volunteers
- 33 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Ovarian Neoplasms, Adnexal Mass
Research and Application of Ultrasonic Intelligent Diagnosis System for Ovarian Mass
Research on automatic detection of ovarian mass and intelligent auxiliary diagnosis system based on multimodal ultrasound images.
- Trial name
- NCT06528236
- Testing
- Artificial intelligence model
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial People's Hospital
Polycystic Ovary Syndrome
The Use Of AMH for the Discrimination of Polycystic and Multicystic Ovaries in Nonhyperandrogenic Patients
AMH is a member of the transforming growth factor family. It is produced by the granulosa cells from 36th weeks of pregnancy.Ovarian granulosa cells are the only source of the antimüllerian hormone.
- Trial name
- NCT01878955
- Testing
- AMH level difference between patient with PCOS and multicystic ovaries.
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Izmir Katip Celebi University
Ovarian Neoplasms
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
Comparison of Nexavar with a placebo as maintenance therapy for patients with advanced Ovarian or primary Peritoneal cancers in complete remission following surgery and one regimen of chemotherapy.
- Trial name
- NCT00791778
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 59 sites in United States, Belgium and 12 more
- Volunteers
- 246 people
- Sponsor
- Bayer
Breast Cancer, Ovarian Cancer
A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services
The goal of this research is to evaluate the relative advantage of remote counseling over usual care in community health practices without access to genetic services.
- Conditions
- Breast Cancer, Ovarian Cancer, Colorectal Cancer
- Trial name
- NCT02517554
- Testing
- Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site, Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site, Patient receives written information on how to find genetic services in their area
- Where
- 7 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Genital Neoplasms, Female
A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
The aim of the trial is to determine the recommended phase II dose of weekly intravenous topotecan in combination with a fixed dose (25 mg or 15 mg) of weekly intravenous temsirolimus in patients with and without prior pelvic…
- Trial name
- NCT00523432
- Testing
- Topotecan, CCI-779 (temsirolimus)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Chicago
Cancer of the Ovary, Cancer of the Fallopian Tube
Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma
Cancer of the ovary and/or peritoneum and/or fallopian tube have a very poor prognosis, and require the implementation of collaborative research tools and new innovative therapies.
- Conditions
- Cancer of the Ovary, Cancer of the Fallopian Tube, Peritoneal Cancer
- Trial name
- BCB-OVAIRE (NCT06969833)
- Testing
- Constitution of a biological collection, Assessment of Quality of Life and level of anxiety/depression
- Where
- France
- Volunteers
- 371 people
- Sponsor
- Centre Oscar Lambret
Polycystic Ovary Syndrome
Oral Administration of DCI to Women With PCOS
To determine if oral DCI administration to women with PCOS increases the total DCI content in urine and blood, and, if so, if that change is accompanied by i) an increase in DCI-IPG release in blood (as determined by bioactivity)…
- Trial name
- PCOS (NCT00497653)
- Testing
- DCI
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Virginia Commonwealth University
Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7
Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This pilot Early Phase I clinical trial studies epacadostat before surgery in treating patients with newly diagnosed stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7
- Trial name
- NCT02042430
- Testing
- Epacadostat, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, NSCLC
Docetaxel Ethanol-induced Symptoms; The Incidence and Risk Forecating Factor
To determine the incidence and risk factors of ethanol-induced symptoms, this multicenter, prospective, observational study is designed to include patients in Korea who are receiving chemotherapy with ethanol-containing docetaxel…
- Conditions
- Breast Cancer, NSCLC, Prostate Cancer, Head and Neck Cancer
- Trial name
- DETECT (NCT04545632)
- Where
- South Korea
- Volunteers
- 458 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Breast Cancer, Bladder Cancer
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
The basic premise of this research proposal is to determine whether there is any significant association between germline polymorphisms and cancers of colon, bladder, breast, testicular, prostate, ovaries, kidney, lung, lymphoid…
- Conditions
- Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer
- Trial name
- NCT00579514
- Testing
- PCR/PCR/LDR Strategy
- Where
- United States
- Volunteers
- 21,081 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Neoplasms, Fallopian Tube Neoplasms
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers.
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
- Trial name
- FRAmework-01 (NCT07213804)
- Testing
- Sofetabart Mipitecan, Paclitaxel, Topotecan
- Where
- 265 sites in United States, Australia and 25 more
- Volunteers
- 1,630 people
- Sponsor
- Eli Lilly and Company
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission
This partially randomized phase I/IIb trial studies the side effects vaccine therapy and indoleamine 2,3-dioxygenase (IDO1) inhibitor 4-amino-1,2,5-oxadizaole-3-carboximidamide (INCB024360) and to see how well they work in…
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IA Fallopian Tube Cancer
- Trial name
- NCT01982487
- Testing
- ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, IDO1 inhibitor INCB024360, laboratory biomarker analysis
- Sponsor
- Roswell Park Cancer Institute
Epithelial Ovarian Cancer
Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer
EXCYTE-1 is a multicentre, prospective observational study to investigate the relationship between ex vivo drug response (EVDR), measured in ovarian tumour-derived samples using high content imaging, and actual patient clinical…
- Trial name
- EXCYTE-1 (NCT06068738)
- Testing
- Biological sample collection
- Where
- 4 sites in Austria, Germany
- Volunteers
- 13 people
- Sponsor
- Exscientia AI Limited
Ovarian Cancer, Fibroids
Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures
The purpose of this research study is to find out which type of transversus abdomens plane (TAP) and block (bupivacaine, liposomal bupivacaine or liposomal bupivacaine with re-dosing at 48-60 hours) improves your pain control and…
- Conditions
- Ovarian Cancer, Fibroids, Uterine Cancer
- Trial name
- NCT04849858
- Testing
- Bupivacaine, Liposomal bupivacaine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of California, Irvine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.